Perritt Capital Management Inc Reduces Position in STRATA Skin Sciences, Inc. (NASDAQ:SSKN)

Perritt Capital Management Inc decreased its holdings in STRATA Skin Sciences, Inc. (NASDAQ:SSKN) by 90.0% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,000 shares of the medical device company’s stock after selling 90,000 shares during the quarter. Perritt Capital Management Inc’s holdings in STRATA Skin Sciences were worth $31,000 at the end of the most recent quarter.

Separately, Azzad Asset Management Inc. ADV lifted its position in STRATA Skin Sciences by 289.5% during the first quarter. Azzad Asset Management Inc. ADV now owns 67,000 shares of the medical device company’s stock valued at $25,000 after purchasing an additional 49,800 shares during the period. 32.43% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other STRATA Skin Sciences news, CEO Dolev Rafaeli purchased 19,100 shares of STRATA Skin Sciences stock in a transaction dated Monday, July 15th. The stock was purchased at an average price of $3.14 per share, with a total value of $59,974.00. Following the transaction, the chief executive officer now directly owns 143,156 shares of the company’s stock, valued at $449,509.84. The purchase was disclosed in a document filed with the SEC, which is available through this link. In related news, Director Uri Geiger bought 230,573 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were bought at an average cost of $3.14 per share, with a total value of $723,999.22. Following the acquisition, the director now owns 1,441,835 shares in the company, valued at $4,527,361.90. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Dolev Rafaeli purchased 19,100 shares of the business’s stock in a transaction on Monday, July 15th. The shares were bought at an average cost of $3.14 per share, with a total value of $59,974.00. Following the acquisition, the chief executive officer now directly owns 143,156 shares of the company’s stock, valued at approximately $449,509.84. The disclosure for this purchase can be found here. Insiders own 40.43% of the company’s stock.

STRATA Skin Sciences Trading Down 0.8 %

Shares of SSKN stock opened at $3.20 on Thursday. The company has a current ratio of 1.14, a quick ratio of 0.92 and a debt-to-equity ratio of 1.59. STRATA Skin Sciences, Inc. has a 12-month low of $2.51 and a 12-month high of $10.00. The stock has a market capitalization of $11.20 million, a P/E ratio of -0.97 and a beta of 1.37. The firm’s 50 day moving average is $3.16 and its 200 day moving average is $3.87.

STRATA Skin Sciences (NASDAQ:SSKN) last released its quarterly earnings results on Wednesday, August 14th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter. The firm had revenue of $8.44 million during the quarter. STRATA Skin Sciences had a negative return on equity of 50.45% and a negative net margin of 25.40%. Research analysts expect that STRATA Skin Sciences, Inc. will post -1 earnings per share for the current year.

About STRATA Skin Sciences

STRATA Skin Sciences, Inc, a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.